SDB-005
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| ChemSpider | 30922481 |
| Chemical and physical data | |
| Formula | C23H22N2O2 |
| Molar mass | 358.17 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[1] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analogue of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.
The code number SDB-005 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM).[2]
However SDB-005 was subsequently used as the name for the indazole-3-carboxylate compound mentioned above when it was sold in Europe as a designer drug, and was entered into the EMCDDA synthetic drug database under this name.[3] Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005.
See also
References
- ↑ "SDB-005". Cayman Chemical. Retrieved 27 June 2015.
- ↑ "The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse". ABS Chemical Neuroscience. 4 (7): 1081–1092. July 2013. doi:10.1021/cn400035r. PMC 3715837
. PMID 23551277. - ↑ EWS_EU: Neue Psychoaktive Substanzen, April 2015